Universal Beteiligungs und Servicegesellschaft mbH Increases Stock Holdings in Twist Bioscience Corporation $TWST

Universal Beteiligungs und Servicegesellschaft mbH lifted its position in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 822.2% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 65,590 shares of the company’s stock after acquiring an additional 58,478 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Twist Bioscience were worth $1,846,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in TWST. Campbell & CO Investment Adviser LLC increased its holdings in Twist Bioscience by 227.6% during the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 47,200 shares of the company’s stock valued at $1,328,000 after acquiring an additional 32,792 shares in the last quarter. Conestoga Capital Advisors LLC increased its stake in shares of Twist Bioscience by 95.8% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 55,600 shares of the company’s stock worth $1,565,000 after purchasing an additional 27,210 shares in the last quarter. Peregrine Capital Management LLC raised its position in shares of Twist Bioscience by 34.9% during the 3rd quarter. Peregrine Capital Management LLC now owns 292,153 shares of the company’s stock worth $8,221,000 after purchasing an additional 75,571 shares during the last quarter. Benjamin Edwards Inc. raised its position in shares of Twist Bioscience by 18.4% during the 3rd quarter. Benjamin Edwards Inc. now owns 28,323 shares of the company’s stock worth $797,000 after purchasing an additional 4,410 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in Twist Bioscience by 203.2% in the 3rd quarter. SG Americas Securities LLC now owns 16,984 shares of the company’s stock valued at $478,000 after buying an additional 11,383 shares in the last quarter.

Wall Street Analyst Weigh In

Several research firms have weighed in on TWST. Evercore ISI reissued an “outperform” rating and set a $42.00 price target on shares of Twist Bioscience in a research report on Monday, January 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, December 29th. Barclays boosted their target price on shares of Twist Bioscience from $37.00 to $39.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. TD Cowen restated a “buy” rating on shares of Twist Bioscience in a report on Thursday, January 8th. Finally, Stephens initiated coverage on shares of Twist Bioscience in a report on Monday, November 3rd. They set an “overweight” rating and a $41.00 price target for the company. Eight analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $44.67.

Twist Bioscience Stock Down 1.2%

Shares of NASDAQ:TWST opened at $41.07 on Friday. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $54.74. The stock’s 50-day moving average price is $35.25 and its two-hundred day moving average price is $31.63. The firm has a market cap of $2.52 billion, a price-to-earnings ratio of -31.35 and a beta of 2.19. The company has a current ratio of 3.64, a quick ratio of 3.33 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.05). Twist Bioscience had a negative return on equity of 27.40% and a negative net margin of 20.63%.The company had revenue of $99.01 million for the quarter, compared to analysts’ expectations of $97.40 million. On average, research analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Insider Transactions at Twist Bioscience

In other news, insider Dennis Cho sold 1,019 shares of the firm’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $32.08, for a total value of $32,689.52. Following the transaction, the insider directly owned 120,694 shares in the company, valued at $3,871,863.52. This trade represents a 0.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Emily M. Leproust sold 4,887 shares of Twist Bioscience stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $32.08, for a total value of $156,774.96. Following the completion of the transaction, the chief executive officer directly owned 733,922 shares in the company, valued at $23,544,217.76. This represents a 0.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 15,090 shares of company stock worth $522,015 over the last ninety days. 3.08% of the stock is owned by insiders.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.